SCHEMBL2960747

SCHEMBL2960747

CCC(O)c1cc2cc(OC)ccc2cc1O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.47
TYR P14679 1/20 0.47
ACHE P22303 1/20 0.47
AKR1C3 P42330 6/20 0.46
AKR1C2 P52895 6/20 0.46
PTGS1 P23219 3/20 0.46
AKR1C1 Q04828 1/20 0.46
ADRA2A P08913 1/20 0.43
ADRA1A P35348 1/20 0.43
ABCB11 O95342 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2A6 P11509 1/20 0.42
KDM4E B2RXH2 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
PTGS2 P35354 1/20 0.39
CDC42 P60953 1/20 0.39
RAC1 P63000 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22313388 0.84 ABCB11 (0.50) BCHETYRACHEAKR1C3AKR1C2
SCHEMBL28957756 0.83 TYR (0.59) BCHETYRACHEADRA2AADRA1A
SCHEMBL16504443 0.83 ADRA2A (0.51) BCHETYRACHEADRA2AADRA1A
SCHEMBL22214036 0.80 CYP1A2 (0.52) AKR1C3AKR1C2PTGS1ABCB11CYP1A2
SCHEMBL2975910 0.80 CYP1A2 (0.52) AKR1C3AKR1C2PTGS1ABCB11CYP1A2
SCHEMBL22313717 0.80 ABCB11 (0.49) BCHETYRACHEAKR1C3AKR1C2
SCHEMBL22393854 0.78 ABCB11 (0.45) BCHETYRACHEAKR1C3AKR1C2
SCHEMBL15086617 0.77 CYP1A2 (0.60) TYRAKR1C3AKR1C2PTGS1ABCB11
SCHEMBL10382340 0.77 AKR1C3 (0.62) AKR1C3AKR1C2PTGS1AKR1C1ABCB11
SCHEMBL15087422 0.77 AKR1C3 (0.62) AKR1C3AKR1C2PTGS1AKR1C1ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776872-B2 Diaminopyrimidines as P2X3 and P2X2/3 modulators ROCHE PALO ALTO LLC (US) 2010-08-17 US disclosed
US-20070049610-A1 Diaminopyrimidines as P2X3 and P2X2/3 modulators ROCHE PALO ALTO LLC 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049610-A1 Diaminopyrimidines as P2X3 and P2X2/3 modulators P2RX3, P2RX6, P2RX2 BCHE 3997/4885TYR 1377/4885ACHE 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.